+44 (0)20 8817 5296info@tritrials.com

Resources

OPRA – technology walk through and latest features

(Expired) Learn how OPRA has been designed to support the four pillars of RBM: Identify, Manage, Mitigate and Report. See the new features in the latest evolution of OPRA, and learn how TRI are continually improving the system in order to support any company wishing to benefit from quality oversight and risk-based monitoring. Who should attend: Existing customers of…

Read More

Protocol Risk Assessment and Designing Site Quality Risk Indicators

(Expired) Within this webinar, we will: – Illustrate the process of using the outputs of protocol risk assessment to identify protocol risk indicators – Illustrate the process of designing protocol risk indicators – Explore the characteristics of good indicators of site quality risk – Explore the practical application of surrogate risk indicators in RBM

Read More

Free Webinar – ICH GCP E6 Revision 2

(Expired) ICH GCP E6 revision 2 is due to be finalized this summer and implemented later this year. The impact on any company running clinical trials is going to be significant. Companies need to start planning now to ensure adequate time for change management and implementation to occur. This free webinar, focusing on quality management, will allow companies to quickly…

Read More

TRI Position Paper – Designing Risk Metrics 22Oct2013

1. Background Triumph Research Intelligence (TRI) was founded as a subsidiary of Triumph Consultancy Services in 2013, following 12 years of consulting to the clinical trial industry. Over the past 12 months TRI has been evaluating the specific challenges facing the industry when implementing a risk-based monitoring strategy and the various approaches and products being utilized by organizations as…

Read More

OPRA Slide Presentations

Why? If a company wants to take a risk-based approach to monitoring, it must be able to prove it has a quality risk management plan which it executed, measured, and adjusted over time. How? TRI developed a purpose built application based on industry guidance that identifies site quality risk and allows central management of monitoring and risk mitigation activities What? OPRA…

Read More

Protocol Risk Assessment Made Simple

(Expired) Protocol Risk Assessment – limited attendance Why is this webinar so important? Protocol Risk Assessment is the genesis of the new Quality Management section (5) of ICH E6 (R2) and core to the principles of quality by design (QBD). It drives much of the downstream quality planning and management activity during the course of a clinical trial and…

Read More

TransCelerate RBM Volume II 15JUL2014

TransCelerate’s Risk-Based Monitoring (RBM) project has been productive in the first half of 2014. The purpose of RBM Update Volume II is to share new and relevant information on the accomplishments of the RBM workstream including the following: RACT version 2.0 released on April 29, 2014 Central Monitoring Capability Technology Considerations to Enable RBM External Engagement Upcoming Deliverables in…

Read More

TransCelerate RBM Volume I 27JAN2014

TransCelerate’s Risk-Based Monitoring (RBM) project had a very productive year in 2013. Subsequent to publishing the Position Paper on Risk-Based Monitoring Methodology in May 2013, we have actively worked to network the concepts and embarked on piloting and/or assessing experience among companies that implemented the methodology. The purpose of this RBM Update document is to share the following information…

Read More

TransCelerate RBM Position Paper 30May2013

Current On-site Monitoring practices are frequency-based, conform to a prescribed monitoring visit schedule, and provide generalized quality control at investigational sites. Although this practice does provide a level of control, advances in risk-based approaches and technology provide an opportunity for a more holistic and proactive approach through Off-site and Central Monitoring and a targeted approach to On-site Monitoring. By…

Read More

FDA Guidance on RBM (2013)

This guidance assists sponsors of clinical investigations in developing risk-based monitoring strategies and plans for investigational studies of medical products, including human drug and biological products, medical devices, and combinations thereof. The overarching goal of this guidance is to enhance human subject protection and the quality of clinical trial data by focusing sponsor oversight on the most important aspects…

Read More

EMA Reflection Paper on RBM (2013)

Good clinical practice (GCP)1 is a set of internationally recognised ethical and scientific standards for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials. ICH GCP requires in Section 5.1, that the sponsor implements and maintains systems for quality assurance and quality control; similarly the Article 2 of the GCP Directive 2005/28/EC requires the implementation…

Read More

Large Pharma RBM Implementation

Our client had strong ambitions to implement both risk-based monitoring (RBM) systems and processes across the entire global organization by the end of 2015. They had chosen a system to adapt to their needs and planned to work to the TransCelerate key risk indicators (KRIs). They needed support in developing the technology to meet their needs, needed guidance on…

Read More

ICD E6 (R2) EMA Adopted Guidelines (Jan 2017)

Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that…

Read More

TRI to sponsor 8th annual Clinical Quality Oversight Forum

8th Annual Clinical Quality Oversight Forum With the adoption of ICH E6 (R2) by the EMA this month, and planned adoption for the FDA later this year, this event has never been more important or relevant to the way in which we conduct and oversee clinical trials. TRI’s CEO Duncan Hall will be presenting alongside Advanced Clinical’s SVP of…

Read More